Company’s 36-month beta value is 1.15.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 117.06M, and currently, short sellers hold a 8.72% ratio of that floaft. The average trading volume of ATAI on December 18, 2024 was 1.28M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATAI) stock’s latest price update
ATAI Life Sciences N.V (NASDAQ: ATAI) has seen a decline in its stock price by -5.32 in relation to its previous close of 1.32. However, the company has experienced a -15.55% decline in its stock price over the last five trading sessions. proactiveinvestors.com reported 2024-11-14 that atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai’s third quarter results earlier this week, the analysts repeated their ‘Buy’ rating on the stock and awarded it a $5 price target, implying upside of 242% from its share price at the time of writing.
ATAI’s Market Performance
ATAI’s stock has fallen by -15.55% in the past week, with a monthly drop of -25.16% and a quarterly drop of -0.81%. The volatility ratio for the week is 7.77% while the volatility levels for the last 30 days are 9.84% for ATAI Life Sciences N.V The simple moving average for the last 20 days is -18.90% for ATAI stock, with a simple moving average of -18.01% for the last 200 days.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at -8.68% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.15% of loss for the given period.
Volatility was left at 9.84%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares sank -27.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.27% upper at present.
During the last 5 trading sessions, ATAI fell by -15.81%, which changed the moving average for the period of 200-days by -38.01% in comparison to the 20-day moving average, which settled at $1.5408. In addition, ATAI Life Sciences N.V saw -11.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of ATAI Life Sciences N.V, valued at $16,093,000 using the latest closing price.
Brand Florian sale 151,303 shares at $1.92 during a trade that took place back on May 16 ’24, which means that Brand Florian is holding 328,697 shares at $290,502 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -319.87 for the present operating margin
- 0.2 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -388.53. The total capital return value is set at -0.6. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.48. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -36.98.
Currently, EBITDA for the company is -36.31 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 604.96. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In a nutshell, ATAI Life Sciences N.V (ATAI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
